ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pertuzumab

Also written as “Pertuzumab”, “Pertuzumab IV” and “Perjeta”.

Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Prostatic Neoplasms, led by 6 companies.

Drug pagePertuzumab: every studyMany companies study it; this page follows only the 46 they lead. All 156 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 13, 201546 company-led studies, 3 open or runningNext primary completion: Mar 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only411 open or runningphase 4since May 13, 2015Nov 15, 2001Mar 28, 2027phase 3 · NCT02320435
Cinnagenits history only10 open or runningphase 3since Jun 22, 2021Jun 22, 2021none ahead
CSPC Pharmaceutical Group11 open or runningphase 3since Nov 25, 2022Nov 25, 2022none ahead
Mabscaleits history only11 open or runningphase 1since Apr 11, 2023Apr 11, 2023none ahead
Sarah Cannon Research Instituteits history only10 open or runningphase 2since Aug 27, 2014Aug 27, 2014none ahead
Zydus Lifesciencesits history only10 open or runningphase 3since Feb 26, 2022Feb 26, 2022none ahead

Also a collaborator on its studies: Daiichi Sankyo and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2022Named pertuzumabINNProposed as its International Nonproprietary Name in WHO's List 126
  2. Nov 25, 2022First study: phase 3 study in HER2-positive Breast CancerFirst studyNCT05720026 · 560 planned · China

TargetBeta

ERBB2 →read by rule
“A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

The one study CSPC Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05720026HER2-positive Breast Cancer · China3RecruitingAug 29, 2025560

How it is read

Names in the registry

  • “Pertuzumab”, 36 entries
  • “Pertuzumab IV”, 4 entries
  • “Perjeta”, 3 entries
  • “pertuzumab”, 2 entries
  • “RhuMab 2C4”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.